Alcon News

1. Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia

   • Presbyopia is an eye condition that is part of natural aging affecting nearly 2 billion people worldwide.[1]
      
   • Dailies Total1® Multifocal contact lenses provide a seamless visual experience offering an alternative to bifocals or reading glasses.
      
   • They are designed to uniquely address end-of-day dryness and discomfort many contact lens wearers experience after age 40.[4]-[10]

   Basel, July 14, 2016 -Alcon, the global leader in eye care and a...

2. Addressing discomfort through contact lens innovation

   Graduate student Evan Sullivan switched to contact lenses, as they give him the freedom to enjoy his college lifestyle, work out at the gym and spend time on the beach without having to worry about his glasses while he is there.

   
   ...

3. Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress

   • Clareon^®intraocular lens (IOL) implanted with a unique single-use automated pre-loaded delivery system debuts with new data presentations
      
   • Congress program highlights Alcon's 70-year legacy of innovation including 100 million AcrySof^®IOL implants
      
   • New analyses show efficacy and safety of CyPass^® Micro-Stent in patients with glaucoma

   Basel, October 2, 2017 - Alcon, the global leader in eye care and a division of Novartis, will introduce Clareon^®, the...

4. Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London

   • Alcon is the global leader in the highly attractive and growing $23 billion eye care devices market
   • Market leading development capabilities and innovation investments
   • Clearly defined near and long-term strategy, focused on sales growth, operational excellence and free cash flow generation
   • 20,000+ employees dedicated to eye care, with a strong and experienced management team
   • Disciplined capital allocation strategy outlined

   New York, November 27, 2018 - Alcon, the eye care...

5. Alcon receives CE Mark for first-of-its-kind AutonoMe(TM) preloaded intraocular lens (IOL) delivery system with Clareon® IOL

   • AutonoMe(TM) preloaded IOL delivery system provides easy, intuitive control for precise IOL insertion during cataract surgery
      
   • New Clareon^® IOL in vitro data and early clinical experience to be presented at European Society of Cataract & Refractive Surgeons congress

   Basel, October 6, 2017 -Alcon, the global leader in eye care and a division of Novartis, has achieved European CE Mark for the Clareon^® IOL with the AutonoMe(TM) delivery system.  AutonoMe(TM) is the...

6. Alcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery

   • Innovative AcrySof^® IQ PanOptix^® Toric intraocular lens (IOL) extends Alcon's trifocal PanOptix^® IOL portfolio to a wider range of patients
      
   • CE-marked in November 2016, this IOL offers excellent near-to-intermediate vision, and increased independence from glasses while addressing astigmatism
      
   • More than 70 percent of patients worldwide undergoing cataract surgery have treatable levels of astigmatism[1]

   BASEL, Switzerland,January 26, 2017 - Alcon, the...

7. Novartis International AG: Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery

   • Better visual outcomes for patients with the AcrySof IQ PanOptix intraocular lens at near and intermediate distance vision[1]
      
   • Detailed findings presented at World Ophthalmology Congress 2018
      
   • Recent survey reveals 82% of people 60+ are willing to have advanced surgical options to treat their cataracts and at the same time improve their vision[2]

   Basel, June 18, 2018   Alcon, the global leader in eye care and a division of Novartis, unveils new data showing significantly improved near and intermediate...

8. Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters

   • Q3 net sales (-1% cc[2] and USD) broadly in line with prior year due to strong performance of Growth Products
     
     • Gilenya(USD 790 million, +15% cc) continued double-digit growth
     • Cosentyx (USD 301 million) on track for blockbuster status in first full year after approval
     • Oncology growth drivers including Tafinlar + Mekinist(USD 172 million, +29% cc), Promacta/Revolade (USD 168 million, +44% cc) and Jakavi (USD 149 million, +47% cc)
     • Sandoz Biopharmaceuticals[1] (USD 262...